e-learning
resources
Barcelona 2013
Tuesday, 10.09.2013
COPD drugs: new findings
Login
Search all ERS
e-learning
resources
Disease Areas
Airways Diseases
Interstitial Lung Diseases
Respiratory Critical Care
Respiratory Infections
Paediatric Respiratory Diseases
Pulmonary Vascular Diseases
Sleep and Breathing Disorders
Thoracic Oncology
Events
International Congress
Courses
Webinars
Conferences
Research Seminars
Journal Clubs
Publications
Breathe
Monograph
ERJ
ERJ Open Research
ERR
European Lung White Book
Handbook Series
Guidelines
All ERS guidelines
e-learning
CME Online
Case reports
Short Videos
SpirXpert
Procedure Videos
CME tests
Reference Database of Respiratory Sounds
Radiology Image Challenge
Brief tobacco interventions
EU Projects
VALUE-Dx
ERN-LUNG
ECRAID
UNITE4TB
Disease Areas
Events
Publications
Guidelines
e-learning
EU Projects
Login
Search
Limitations for the inclusion of patients in the Roflu-2011 study
A. Gómez-Bastero, A. Valido, C. Romero, P. Guerrero, L. Mechbal, T. Montemayor (Seville, Spain)
Source:
Annual Congress 2013 –COPD drugs: new findings
Session:
COPD drugs: new findings
Session type:
Thematic Poster Session
Number:
4142
Disease area:
Airway diseases
Rating:
You must
login
to grade this presentation.
Share or cite this content
Citations should be made in the following way:
A. Gómez-Bastero, A. Valido, C. Romero, P. Guerrero, L. Mechbal, T. Montemayor (Seville, Spain). Limitations for the inclusion of patients in the Roflu-2011 study. Eur Respir J 2013; 42: Suppl. 57, 4142
You must
login
to share this Presentation/Article on Twitter, Facebook, LinkedIn or by email.
Member's Comments
No comment yet.
You must
Login
to comment this presentation.
Related content which might interest you:
The Relationship Between Functional Status and Fatigue After COVID-19 Infection
Observational cohort study of pulmonary exacerbations in alpha-1 antitrypsin deficiency
Panel discussion on ERS Statement – A core outcome set for clinical trials evaluating the management of COPD exacerbations
Related content which might interest you:
Clinical characteristics of patients with frequent COPD exacerbations in a Swiss multicenter COPD cohort study (TOPDOCS)
Source: International Congress 2016 – Targeting care, pulmonary rehabilitation, management, and self-management of COPD exacerbations in primary care
Year: 2016
Effect of exacerbation history and ICS use on outcomes in COPD patients from the TIOSPIR™ trial
Source: International Congress 2015 – New data on established treatments for COPD
Year: 2015
Top-10 comorbidities of symptomatic patients with moderate COPD in the clinical setting of the CRYSTAL study
Source: International Congress 2016 – Features and impact of comorbidities in COPD
Year: 2016
Lung function and treatment patterns of symptomatic patients with moderate COPD in the CRYSTAL study
Source: International Congress 2016 – Novel avenues in the treatment of COPD I
Year: 2016
COPD severity analysis according to current evaluation criteria – National survey
Source: International Congress 2015 – Clinical assessment and monitoring of asthma and COPD
Year: 2015
Comparison of COPD patients with high and low symptoms from a real-world US survey
Source: International Congress 2015 – Non-inflammatory monitoring of airway diseases
Year: 2015
Implications of under treatment of stable COPD (SAVING study)
Source: International Congress 2015 – New data on established treatments for COPD
Year: 2015
Bacterial profile and antibiotic susceptibility from patients with exacerbation of COPD: 10 – years prospective study
Source: International Congress 2016 – Microbiological issues and translational research in respiratory infections
Year: 2016
Real-life COPD patients compared to large trial populations: An UNLOCK external validity study
Source: Annual Congress 2013 –Management of respiratory diseases in primary care
Year: 2013
Real-life study on the aPpropriaTeness of treatment in moderate COPD patients (OPTIMO)
Source: Annual Congress 2013 –COPD drugs: new findings
Year: 2013
QVA149 reduces COPD exacerbation rate in various subgroups of patients: The SPARK study
Source: Annual Congress 2013 –New bronchodilators for COPD management
Year: 2013
Efficacy and safety of erdosteine in COPD: Results of a 12-month prospective, multinational study
Source: International Congress 2015 – New data on established treatments for COPD
Year: 2015
Measuring exacerbations in subjects with mild to moderate COPD from a population-based cohort: The CanCOLD study
Source: Annual Congress 2013 –Factors associated with outcomes in COPD
Year: 2013
Estimation of tiotropium efficacy at the COPD patients with group D
Source: International Congress 2015 – Different data in COPD
Year: 2015
Methodologies for study of COPD exacerbations
Source: Annual Congress 2012 - ERS COPD exacerbation guidelines: methodologies and overview
Year: 2012
Impact of age-related comorbidities on the risk of COPD exacerbations in subjects with severe airflow limitation: A pan-European study
Source: Annual Congress 2013 –COPD mechanisms
Year: 2013
Influence of patient baseline characteristics and concomitant medication on outcomes in long-term trials of COPD: Analysis of the UPLIFT® trial
Source: Annual Congress 2013 –Clinical trials of LAMAs, LABAs, MABAs and theophylline for asthma and COPD
Year: 2013
Efficacy of tiotropium/olodaterol on sedentary/active time in COPD patients: VESUTO study
Source: International Congress 2018 – COPD management
Year: 2018
Baseline symptom scores and future risk of severe exacerbation: The SPARK study
Source: International Congress 2015 – New data on established treatments for asthma and COPD
Year: 2015
The relationship between 24-hour symptoms and COPD exacerbations: Results from ASSESS
Source: International Congress 2014 – COPD exacerbations
Year: 2014
We use cookies on our website to give you the most relevant experience by remembering your preferences and repeat visits. By clicking "Accept", you consent to the use of the cookies.
Accept